AD Pain, Sleep Scales Validated in Phase 3 Trials
January 14, 2026
-
3 min
A psychometric analysis published in Dermatology and Therapy reveals that 3-point and 4-point reductions on the Skin Pain Numeric Rating Scale (SP-NRS) and Sleep Disturbance Numeric Rating Scale (SD-NRS) indicate clinically significant improvement in patients with moderate-to-severe atopic dermatitis. The study analyzed data from three phase 3 trials of rocatinlimab, emphasizing how skin pain and sleep disturbances are crucial patient-reported outcomes beyond itch severity, and aligning with patients' perceptions of treatment benefits.
1. 3-point and 4-point reductions on SP-NRS and SD-NRS are clinically meaningful. 2. The study analyzed data from three phase 3 trials of rocatinlimab. 3. Skin pain and sleep disturbance are important outcomes in atopic dermatitis. 4. Intraclass correlation coefficients of at least 0.80 indicate high test-retest reliability. 5. Patient experiences captured by SP-NRS and SD-NRS may differ from clinician assessments.
Listen Tab content
